About this page
Insider trades reported on SEC Form 4: when the people who run a company buy or sell its shares with their own money.
How to read it
- Form 4
- The form a company insider (officer, director or owner of more than 10%) must file with the SEC within two business days of buying or selling the company's shares.
- Buy (P) and Sell (S)
- Open-market purchases and sales. Gifts, option exercises and automatic tax withholding are left out because they say little about what the insider thinks.
- Value
- Shares times price, as reported on the filing.
- 10b5-1
- A trade made under a plan set up in advance. Planned sales are common and usually say less than an unplanned purchase.
- Late filing
- A Form 4 filed more than two business days after the trade.
- Vs. S&P 500
- How the stock did after the trade minus how the overall market did in the same weeks.
A real example
In January 2016, when bank stocks were falling, JPMorgan Chase CEO Jamie Dimon bought 500,000 JPMorgan shares with his own money, worth about $26 million. His Form 4 made the purchase public within days, and investors read it as a strong sign of confidence.
Explain it like I'm 13
If the coach of a team bets his own allowance that his team will win, that tells you something. A Form 4 is the note a company boss must hand in whenever he buys or sells his own company's shares, so everyone can see it.
Data from public SEC filings and congressional reports. Information, not investment advice. Check every number against the filing linked on the page.
CORCEPT THERAPEUTICS INC (CORT): Insider Trades and Fund Holdings
In the past 12 months, CORCEPT THERAPEUTICS INC insiders reported no open-market purchases and 17 sales worth $39.9M; 15 of the sales were reported as made under a 10b5-1 trading plan.
Timeline: news and trades
Company filings (8-K), insider trades, notices of planned sales (Form 144) and fund moves in the past year, newest first.
- Oct 15, 2026Insider saleDirector James N. Wilson sold $1.1 million under a 10b5-1 plan
- Oct 2, 2026Insider saleSee Remarks Sean Maduck sold $2.9 million under a 10b5-1 plan (9 days after: executive or director change)
- Oct 2, 2026Insider saleSee Remarks Joseph Douglas Lyon sold $1.1 million under a 10b5-1 plan (9 days after: executive or director change)
- Oct 2, 2026Insider salePresident Roberto Wandenkolk Vieira sold $967,448 under a 10b5-1 plan (9 days after: executive or director change)
- Oct 1, 2026Insider saleSee Remarks Joseph Douglas Lyon sold $93,473 under a 10b5-1 plan (8 days after: executive or director change)
- Oct 1, 2026Insider saleSee Remarks Sean Maduck sold $47,717 under a 10b5-1 plan (8 days after: executive or director change)
- Oct 1, 2026Planned saleLyon Joseph Douglas (officer) filed notice to sell about $1.2 million around Oct 1, 2026
- Sep 23, 2026NewsCompany reported: Executive or director change
- Sep 16, 2026Insider salePresident Roberto Wandenkolk Vieira sold $29,843 under a 10b5-1 plan
- Sep 15, 2026Insider saleDirector James N. Wilson sold $1.1 million under a 10b5-1 plan
- Sep 15, 2026Planned saleWILSON JAMES N (director) filed notice to sell about $3.3 million around Sep 15, 2026
- Sep 14, 2026Insider saleSee Remarks Joseph Douglas Lyon sold $1.1 million under a 10b5-1 plan
- Sep 14, 2026Planned saleLyon Joseph Douglas (officer) filed notice to sell about $1.1 million around Sep 14, 2026
- Sep 2, 2026Insider salePresident Roberto Wandenkolk Vieira sold $6.5 million under a 10b5-1 plan
- Sep 2, 2026Planned saleVieira Roberto Wandenkolk (officer) filed notice to sell about $8.3 million around Sep 2, 2026
- Sep 1, 2026Insider saleSee Remarks Sean Maduck sold $2.9 million under a 10b5-1 plan
- Aug 26, 2026Insider saleDirector Kimberly Park sold $3.3 million
- Aug 26, 2026Planned saleKIMBERLY PARK (director) filed notice to sell about $3.3 million around Aug 26, 2026
- Aug 25, 2026Insider saleSee Remarks Sean Maduck sold $3.9 million under a 10b5-1 plan
- Aug 25, 2026Planned saleMaduck Sean (officer) filed notice to sell about $22 million around Aug 25, 2026
- Aug 18, 2026Insider saleDirector David L. Mahoney sold $12.3 million under a 10b5-1 plan
- Aug 18, 2026Planned saleMAHONEY DAVID L (director) filed notice to sell about $12.2 million around Aug 18, 2026
- Aug 17, 2026Insider saleChief Business Officer Gary Charles Robb sold $1.2 million
- Aug 17, 2026Planned saleRobb Gary Charles (officer) filed notice to sell about $1.2 million around Aug 17, 2026
- Aug 14, 2026Insider saleDirector James N. Wilson sold $1.1 million under a 10b5-1 plan
- Aug 14, 2026Insider saleSee Remarks Sean Maduck sold $419,491 under a 10b5-1 plan
- Jun 30, 2026FundBridgewater Associates added 50% in Q2 2026 (13F filed Aug 14, 2026)
- Jun 30, 2026FundRenaissance Technologies cut 7% in Q2 2026 (13F filed Aug 13, 2026)
Recent insider trades
Open-market purchases (code P) and sales (code S) from Form 4. Grants, option exercises and gifts are not shown. Latest filing: Oct 16, 2026.
| Filed | Insider | Type | Value |
|---|---|---|---|
| Oct 16 | James N. WilsonDirector | ▼ SELL10b5-1 | $1.15M |
| Oct 5 | Sean MaduckSee Remarks | ▼ SELL10b5-1 | $2.86M |
| Oct 5 | Joseph Douglas LyonSee Remarks | ▼ SELL10b5-1 | $1.07M |
| Oct 5 | Roberto Wandenkolk VieiraPresident | ▼ SELL10b5-1 | $967K |
| Oct 5 | Joseph Douglas LyonSee Remarks | ▼ SELL10b5-1 | $93K |
| Oct 5 | Sean MaduckSee Remarks | ▼ SELL10b5-1 | $48K |
| Sep 18 | Roberto Wandenkolk VieiraPresident | ▼ SELL10b5-1 | $30K |
| Sep 16 | Joseph Douglas LyonSee Remarks | ▼ SELL10b5-1 | $1.13M |
| Sep 16 | James N. WilsonDirector | ▼ SELL10b5-1 | $1.11M |
| Sep 3 | Roberto Wandenkolk VieiraPresident | ▼ SELL10b5-1 | $6.46M |
Insiders who traded in the past year
| Insider | Role | Buys | Bought | Sells | Sold |
|---|---|---|---|---|---|
| James N. Wilson | Director | 0 | $0 | 3 | $3.37M |
| Sean Maduck | See Remarks | 0 | $0 | 5 | $10.1M |
| Joseph Douglas Lyon | See Remarks | 0 | $0 | 3 | $2.30M |
| Roberto Wandenkolk Vieira | President | 0 | $0 | 3 | $7.46M |
| Kimberly Park | Director | 0 | $0 | 1 | $3.27M |
| David L. Mahoney | Director | 0 | $0 | 1 | $12.3M |
| Gary Charles Robb | Chief Business Officer | 0 | $0 | 1 | $1.16M |
Buybacks and executive pay
CORCEPT THERAPEUTICS INC spent $172.9 million buying back its own shares in 2025.
| Year | CEO pay reported | CEO pay "actually paid" | Value of $100 invested |
|---|---|---|---|
| 2025 | $15.3M | $14.8M | n/a |
| 2024 | $9.89M | $22.8M | n/a |
| 2023 | $9.34M | $15.8M | n/a |
From the company's XBRL data filed with the SEC. "Actually paid" is the SEC's pay-versus-performance measure, which counts changes in the value of stock awards. "Value of $100 invested" is the company's cumulative shareholder return as reported, usually measured from five years earlier. See all buybacks and CEO pay across companies.
Tracked funds that report CORT
From each fund's latest 13F. Holdings are as of quarter end and are filed up to 45 days later.
| Fund | Shares | Value | Change |
|---|---|---|---|
| Renaissance Technologies | 5,261,628 | $457.5M | ▼ −7.4% |
| Bridgewater Associates | 57,602 | $5.01M | ▲ +49.9% |
Reading these numbers
Insiders sell for many reasons: taxes, diversification, a house. Purchases with their own money are rarer and are usually read as more informative. A Form 4 is due within two business days of the trade. How to read a Form 4 →